Skip to content

CorMedix CRMD Other accrued liabilities

Other accrued liabilities at other companies

Abbott logo
AbbottABT
ICU Medical logo
ICU MedicalICUI
Medline, Inc.
 logo
Medline, Inc. MDLN
Solventum logo
SolventumSOLV
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's other accrued liabilities?
CorMedix (CRMD) reported other accrued liabilities of $4.63M in Q1 2026.
How has CorMedix's other accrued liabilities changed year-over-year?
CorMedix's other accrued liabilities increased by 5197.2% year-over-year, from $87.42K to $4.63M.
What is the long-term trend for CorMedix's other accrued liabilities?
Over 5 years (2020 to 2025), CorMedix's other accrued liabilities has grown at a 99.5% compound annual growth rate (CAGR), from $144K to $4.55M.